Table 1.
Epidemiologic parameters for estimating burden of HPV related cancer in men in the Netherlands
| Cancer site (ICD code) and summary measure | Median value (95% credible interval)* |
|---|---|
| Penis (ICD-C60) | |
| Lifetime risk of diagnosis | 172 (160 to 186)×10–5 |
| HPV attributable fraction | 36% (45% to 65%)50 |
| Proportion HPV 16 positive† | 60% (56% to 64%)52 |
| Proportion HPV 18 positive† | 13% (11% to 16%)52 |
| 10 year relative survival probability‡ | 0.65 (0.58 to 0.71) |
| HPV positive hazard ratio | 0.21 (0.06 to 0.76)49 |
| Anus and anal canal (ICD-C21) | |
| Lifetime risk of diagnosis | 74 (68 to 80)×10–5 |
| Relative risk among MSM§ | 31 (8.2 to 80)36 |
| HPV attributable fraction | 86% (83% to 89%)16 |
| Male:female odds ratio¶ | 0.29 (0.19 to 0.44)16 |
| Proportion HPV 16 positive† | 85% (82% to 87%)53 |
| Proportion HPV 18 positive† | 7% (5% to 10%)53 |
| 10 year relative survival probability‡ | 0.45 (0.38 to 0.52) |
| Oropharynx (ICD-C01, C09, C10) | |
| Lifetime risk of diagnosis | 305 (295 to 316)×10–5 |
| Relative risk among MSM§ | 2.9 (1.3 to 5.4)36 |
| HPV attributable fraction | 29% (19% to 41%)51 |
| Male:female odds ratio¶ | 3.5 (1.4 to 8.6)51 |
| Proportion HPV 16 positive† | 87% (83% to 90%)41 |
| Proportion HPV 18 positive† | 3% (1% to 5%)41 |
| 10 year relative survival probability‡ | 0.23 (0.20 to 0.25) |
| HPV positive hazard ratio | 0.46 (0.37 to 0.57)55 |
*Data from Dutch national cancer registry unless reference number shown.
†Relative contribution among HPV positive cases
‡Cancer specific survival among men aged 45-74;younger men have better survival, older men have worse survival (data not shown).
§Relative risk of cancer among men who have sex with men (MSM) v heterosexual men.
¶Odds ratio for HPV positivity of cancer cases among men compared with women.